BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 8407753)

  • 1. Side effects of methylphenidate and desipramine alone and in combination in children.
    Pataki CS; Carlson GA; Kelly KL; Rapport MD; Biancaniello TM
    J Am Acad Child Adolesc Psychiatry; 1993 Sep; 32(5):1065-72. PubMed ID: 8407753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methylphenidate and desipramine in hospitalized children: I. Separate and combined effects on cognitive function.
    Rapport MD; Carlson GA; Kelly KL; Pataki C
    J Am Acad Child Adolesc Psychiatry; 1993 Mar; 32(2):333-42. PubMed ID: 8444762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation.
    Barkley RA; McMurray MB; Edelbrock CS; Robbins K
    Pediatrics; 1990 Aug; 86(2):184-92. PubMed ID: 2196520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methylphenidate dosing: twice daily versus three times daily.
    Stein MA; Blondis TA; Schnitzler ER; O'Brien T; Fishkin J; Blackwell B; Szumowski E; Roizen NJ
    Pediatrics; 1996 Oct; 98(4 Pt 1):748-56. PubMed ID: 8885956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fenfluramine and methylphenidate in children with mental retardation and ADHD: clinical and side effects.
    Aman MG; Kern RA; McGhee DE; Arnold LE
    J Am Acad Child Adolesc Psychiatry; 1993 Jul; 32(4):851-9. PubMed ID: 8340309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity.
    Research Units on Pediatric Psychopharmacology Autism Network
    Arch Gen Psychiatry; 2005 Nov; 62(11):1266-74. PubMed ID: 16275814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of methylphenidate and lithium on attention and activity level.
    Carlson GA; Rapport MD; Kelly KL; Pataki CS
    J Am Acad Child Adolesc Psychiatry; 1992 Mar; 31(2):262-70. PubMed ID: 1564028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth deficits in children treated with desipramine: a controlled study.
    Spencer T; Biederman J; Wright V; Danon M
    J Am Acad Child Adolesc Psychiatry; 1992 Mar; 31(2):235-43. PubMed ID: 1564024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of theophylline compared to methylphenidate for the treatment of attention-deficit hyperactivity disorder in children and adolescents: a pilot double-blind randomized trial.
    Mohammadi MR; Kashani L; Akhondzadeh S; Izadian ES; Ohadinia S
    J Clin Pharm Ther; 2004 Apr; 29(2):139-44. PubMed ID: 15068402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of late-afternoon methylphenidate administration on behavior and sleep in attention-deficit hyperactivity disorder.
    Kent JD; Blader JC; Koplewicz HS; Abikoff H; Foley CA
    Pediatrics; 1995 Aug; 96(2 Pt 1):320-5. PubMed ID: 7630692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. School observations of children with attention-deficit hyperactivity disorder and comorbid tic disorder: effects of methylphenidate treatment.
    Gadow KD; Nolan E; Sprafkin J; Sverd J
    J Dev Behav Pediatr; 1995 Jun; 16(3):167-76. PubMed ID: 7560119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
    Adler LA; Zimmerman B; Starr HL; Silber S; Palumbo J; Orman C; Spencer T
    J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse side effects of methylphenidate among mentally retarded children with ADHD.
    Handen BL; Feldman H; Gosling A; Breaux AM; McAuliffe S
    J Am Acad Child Adolesc Psychiatry; 1991 Mar; 30(2):241-5. PubMed ID: 2016228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of methylphenidate on the quality of life in children with epilepsy and attention deficit hyperactivity disorder: and open-label study using an osmotic-controlled release oral delivery system.
    Yoo HK; Park S; Wang HR; Lee JS; Kim K; Paik KW; Yum MS; Ko TS
    Epileptic Disord; 2009 Dec; 11(4):301-8. PubMed ID: 20007067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular effects of desipramine in children.
    Schroeder JS; Mullin AV; Elliott GR; Steiner H; Nichols M; Gordon A; Paulos M
    J Am Acad Child Adolesc Psychiatry; 1989 May; 28(3):376-9. PubMed ID: 2661525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative efficacy of long-acting stimulants on children with attention deficit-hyperactivity disorder: a comparison of standard methylphenidate, sustained-release methylphenidate, sustained-release dextroamphetamine, and pemoline.
    Pelham WE; Greenslade KE; Vodde-Hamilton M; Murphy DA; Greenstein JJ; Gnagy EM; Guthrie KJ; Hoover MD; Dahl RE
    Pediatrics; 1990 Aug; 86(2):226-37. PubMed ID: 2196522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.
    Medori R; Ramos-Quiroga JA; Casas M; Kooij JJ; Niemelä A; Trott GE; Lee E; Buitelaar JK
    Biol Psychiatry; 2008 May; 63(10):981-9. PubMed ID: 18206857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of methylphenidate among mentally retarded children with attention deficit hyperactivity disorder.
    Handen BL; Breaux AM; Gosling A; Ploof DL; Feldman H
    Pediatrics; 1990 Dec; 86(6):922-30. PubMed ID: 2135682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder.
    Cox DJ; Merkel RL; Moore M; Thorndike F; Muller C; Kovatchev B
    Pediatrics; 2006 Sep; 118(3):e704-10. PubMed ID: 16950962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.